Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations
- 1 January 1994
- journal article
- review article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 34 (1) , S76-S83
- https://doi.org/10.1007/bf00684868
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditionsCancer Chemotherapy and Pharmacology, 1993
- Factors Affecting In Vitro Protein Binding of Etoposide in HumansJournal of Pharmaceutical Sciences, 1992
- Interspecies differences in in vitro etoposide plasma protein bindingBiochemical Pharmacology, 1991
- Modeling Interpatient Pharmacodynamic Variability of EtoposideJNCI Journal of the National Cancer Institute, 1991
- Clinical pharmacodynamics of continuous-infusion etoposideCancer Chemotherapy and Pharmacology, 1990
- Evaluation of Aminoglycoside Disposition in Patients Previously Treated with CisplatinTherapeutic Drug Monitoring, 1989
- Guide to Drug dosage in Renal Failure1Clinical Pharmacokinetics, 1988
- Drug monitoring of etoposide (VP16-213)Cancer Chemotherapy and Pharmacology, 1987
- Pharmacokinetics of high dose etoposide (VP 16–213)European Journal of Cancer and Clinical Oncology, 1986
- Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratomaCancer Chemotherapy and Pharmacology, 1985